Products
The fixed combination Deanxit with the two active ingredients melitracene and flupentixol is commercially available in many countries in the form of film-coated tablets. The drug has been approved since 1973, initially as dragées. The marketing authorization holder is the Danish company Lundbeck.
Structure and properties
The active ingredients are present in the drug as melitracene hydrochloride and as flupentixol dihydrochloride.
Effects
Flupentixol (ATC N05AF01) is a neuroleptic with antianxiety, antipsychotic, antidepressant, mood-stabilizing, and activating properties. The effects are due in part to antagonism at dopamine receptors. Melitracene (ATC N06AA14) is a tricyclic antidepressant with antidepressant and anticholinergic effects. The effects are based on interaction with neurotransmitter systems.
Indications
For the treatment of mild to moderate states of depressive inhibition and anxiety.
Dosage
According to the prescribing information. The film-coated tablets are usually taken in the morning and at noon.
Contraindications
- Hypersensitivity
- Circulatory collapse
- Alcohol or drug intoxication
- Comatose state
- Pheochromocytoma
- Blood dyscrasias
- Recent myocardial infarction
- Heart block
- Excitation conduction disorders
- Coronary insufficiency
- Concurrent administration of MAO inhibitors.
For complete precautions, see the drug label.
Interactions
Drug-drug interactions have been described with the following agents:
- MAO inhibitors
- Sympathomimetics
- Adrenergic neuron blockers
- Anticholinergics
- Central depressant drugs
- Drugs that prolong the QT interval.
- Lithium
- Levodopa
Adverse effects
The most common possible adverse effects include dry mouth, dizziness, tremor, nervousness, blurred vision, and insomnia.
